Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COLL
COLL logo

COLL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Collegium Pharmaceutical Inc (COLL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
33.610
1 Day change
0.72%
52 Week Range
50.790
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

COLL is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in a weak technical setup, there is no recent positive news catalyst, analysts' view details are unavailable, insiders are selling aggressively, and options sentiment is bearish. With no AI Stock Picker or SwingMax buy signal, I would not recommend buying it now; the clearer call is to hold off.

Technical Analysis

Price is 33.42, basically flat versus the prior close, but the broader setup is bearish. MACD histogram is negative and expanding, RSI_6 at 31.5 is weak/near oversold but not a strong reversal signal, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The price is sitting just above S1 at 33.24 and near S2 at 32.693, which suggests downside pressure remains. The short-term pattern data also points to weak forward expectations, especially over the next month.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bearish. Put open interest (790) is much higher than call open interest (314), producing a high put-call ratio of 2.52. Implied volatility is elevated at 67.01 with IV percentile 84.92, showing expensive options pricing and heightened uncertainty. Today's option volume is zero, so there is no active bullish flow to offset the bearish positioning.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
3

Positive Catalysts

  • No recent news in the last week. The only mild positive is that the stock is slightly above the prior close and near support, which could allow a short-term bounce, but there is no real catalyst-driven upside signal.

Neutral/Negative Catalysts

  • Insiders are selling, and selling activity increased 145.95% over the last month. Hedge funds are neutral with no significant accumulation trend. There is no recent news catalyst, no recent congress trading data, and no AI Stock Picker or SwingMax buy signal. The options market is also heavily tilted toward puts.

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so I cannot confirm recent revenue or earnings trends. The latest quarter season is not available from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible upgrade/downgrade momentum to support a buy thesis. Based on the missing data and the overall setup, Wall Street pros cannot currently be framed as meaningfully bullish on this stock from the provided inputs.

Wall Street analysts forecast COLL stock price to rise
4 Analyst Rating
Wall Street analysts forecast COLL stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.370
sliders
Low
55
Averages
56.75
High
60
Current: 33.370
sliders
Low
55
Averages
56.75
High
60
Truist
Les Sulewski
Buy
maintain
$55 -> $58
AI Analysis
2026-02-10
Reason
Truist
Les Sulewski
Price Target
$55 -> $58
AI Analysis
2026-02-10
maintain
Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Collegium Pharmaceutical to $58 from $55 and keeps a Buy rating on the shares. The firm is positive on the company's Jornay momentum and pain portfolio durability, the analyst tells investors in a research note.
Barclays
Overweight
downgrade
$58 -> $56
2026-01-09
Reason
Barclays
Price Target
$58 -> $56
2026-01-09
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Collegium Pharmaceutical to $56 from $58 and keeps an Overweight rating on the shares. The firm updated the company's' estimates to reflect its initial fiscal 2026 outlook.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COLL
Unlock Now

People Also Watch